1-(4-(2-amino-2-methylpropyl)-3-(trifluoromethyl)phenyl)-3-(2-(5-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)urea;

1-(4-(2-amino-2-methylpropyl)-3-(trifluoromethyl)phenyl)-3-(2-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)urea;

N-(2-(dimethylamino)ethyl)-3-(3-(2-(4-(2-methoxyethoxy)-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)ureido)-5-(trifluoromethyl)benzamide;

1-(4-((dimethylamino)methyl)-2-fluoro-5-(trifluoromethyl)phenyl)-3-(2-(5-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)pyrimidin-5-yl)urea;

N-(2-(dimethylamino)ethyl)-3-(3-(2-(5-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-pyrimidin-5-yl)ureido)-5-(trifluoromethyl)benzamide;

1-(4-((dimethylamino)methyl)-2-fluoro-5-(trifluoromethyl)phenyl)-3-(2-(5-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)urea; or

1-(2-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)-3-(4-((4-ethylpiperazin-1-yl)methyl)-2-fluoro-5-(trifluoromethyl)phenyl)urea;

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to any one of claims 1-15 and a pharmaceutically acceptable excipient.

17. A method of treating irritable bowel syndrome comprising administering to a human in need thereof an effective amount of the compound or pharmaceutically acceptable salt according to any one of claims 1-15.

18. A method of treating cancer comprising administering to a human in need thereof an effective amount of the compound or pharmaceutically acceptable salt according to any one of claims 1-15.

19. The compound or pharmaceutically acceptable salt according to any one of claims 1-15 for use in therapy.

20. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-15 for the treatment of irritable bowel syndrome.

21. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-15 for the treatment of cancer.

22. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-15 in the manufacture of a medicament for the treatment of a disease mediated by RET.

23. The use according to claim 22 wherein the disease is irritable bowel syndrome.

24. The use according to claim 22 wherein the disease is cancer.

1-(4-(2-amino-2-methylpropyl)-3-(trifluoromethyl)phenyl)-3-(2-(5-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)urea;

1-(4-(2-amino-2-methylpropyl)-3-(trifluoromethyl)phenyl)-3-(2-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)urea;

N-(2-(dimethylamino)ethyl)-3-(3-(2-(4-(2-methoxyethoxy)-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)ureido)-5-(trifluoromethyl)benzamide;

1-(4-((dimethylamino)methyl)-2-fluoro-5-(trifluoromethyl)phenyl)-3-(2-(5-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)pyrimidin-5-yl)urea;

N-(2-(dimethylamino)ethyl)-3-(3-(2-(5-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-pyrimidin-5-yl)ureido)-5-(trifluoromethyl)benzamide;

1-(4-((dimethylamino)methyl)-2-fluoro-5-(trifluoromethyl)phenyl)-3-(2-(5-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)urea; or

1-(2-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-4-methylpyrimidin-5-yl)-3-(4-((4-ethylpiperazin-1-yl)methyl)-2-fluoro-5-(trifluoromethyl)phenyl)urea;

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to any one of claims 1-15 and a pharmaceutically acceptable excipient.

17. The compound or pharmaceutically acceptable salt according to any one of claims 1-15 for use in therapy.

18. The compound or pharmaceutically acceptable salt according to any one of claims 1-15 for use in the treatment of irritable bowel syndrome.

19. The compound or pharmaceutically acceptable salt according to any one of claims 1-15 for use in the treatment of cancer.

20. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-15 in the manufacture of a medicament for the treatment of a disease mediated by RET, wherein the disease is irritable bowel syndrome.

21. Use of the compound or pharmaceutically acceptable salt according to any one of claims 1-15 in the manufacture of a medicament for the treatment of a disease mediated by RET, wherein the disease is cancer.